Evidence map›Paper›PMID 32395665›Full record

ArticleAmerican journal of ophthalmology case reports2020

Recurrent fungal endophthalmitis after intravitreal injections of bevacizumab.

Alaa Din Abdin, Shady Suffo, Dina Alnaggar, Loay Daas, Berthold Seitz

Abstract readCase Reports
In one paragraph

Article in American journal of ophthalmology case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Efficacy and safety of intraocular lens removal combined with vitrectomy for acute endophthalmitis in pseudophakic eyes.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alaa Din AbdinDepartment of Ophthalmology, Saarland University Medical Center UKS, 66421, Homburg/Saar, Germany.
Shady SuffoDepartment of Ophthalmology, Saarland University Medical Center UKS, 66421, Homburg/Saar, Germany.
Dina AlnaggarDepartment of Ophthalmology, Saarland University Medical Center UKS, 66421, Homburg/Saar, Germany.
Loay DaasDepartment of Ophthalmology, Saarland University Medical Center UKS, 66421, Homburg/Saar, Germany.
Berthold SeitzDepartment of Ophthalmology, Saarland University Medical Center UKS, 66421, Homburg/Saar, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe intend to describe an uncommon case of recurrent post-cataract fungal endophthalmitis after intravitreal injections of Bevacizumab. OBSERVATIONS: A 73-year-old male, who underwent an uncomplicated cataract surgery 8 months ago, presented to our department with postoperative endophthalmitis 5 days after his fifth intravitreal injection (IVI) of bevacizumab for treatment of cystoid macula edema caused by central retinal venous occlusion 6 months ago. The visual acuity (VA) was 0.1 (20/200). The patient underwent an emergency pars plana vitrectomy. Culture of vitreous tap was negative. Eight weeks later, the patient presented again with recurrent endophthalmitis 2 days after his sixth IVI of bevacizumab. VA was hand motion. The patient was treated with an emergency anterior and posterior segment washout with intracapsular posterior intraocular lens (pIOL) extraction. Culture of pIOL revealed CONCLUSIONS AND IMPORTANCE: we assume that this is a rare case of chronic late-onset post-cataract fungal endophthalmitis, which was activated by repeated intravitreal injections of Bevacizumab.

Indexed as

BevacizumabFungal endophthalmitisIntravitreal injectionsSaccharomyces cervisiae

Identifiers

PMID32395665
PMCPMC7206407

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.